日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / State Council News

Nation issues new anti-monopoly guidelines for pharma sector

By Li Jiaying | chinadaily.com.cn | Updated: 2025-01-24 21:04
Share
Share - WeChat
Pharmacists dispense drugs at a hospital in Huzhou, Zhejiang province, in August. YI FAN/FOR CHINA DAILY

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly commission officially issued new anti-monopoly guidelines on Friday targeting the pharmaceutical sector. 

A key highlight of the guidelines lies in the involvement of online platforms' monopolistic regulations. Given the rapid growth of online medical consultations and pharmaceutical e-commerce, the guidelines, for the first time, incorporate measures to address monopolistic practices in online medicine businesses, prohibiting platforms from engaging in the misuse of data, algorithms or platform rules.

The broad scope of the new guidelines also merits attention, which encompasses the entire pharmaceutical product chain — including traditional Chinese medicine, chemical drugs and biological products — compared to the previous version, which was largely concentrated in the limited realm of chemical active pharmaceutical ingredients (APIs).

"The pharmaceutical industry is highly technology-driven. Besides APIs, it also includes innovative drugs, patented medicines and generics. Every stage — from procurement and R&D to production, distribution and generic development — involves significant technological advancements and related protective strategies," said Zhou Wei, deputy director of the health law research center at Wuhan University, in an earlier interview. 

To further combat "false innovation", the guidelines also address a new type of patent monopoly behavior known as "product hopping". 

Product hopping refers to a strategy employed by original drug manufacturers to avoid or reduce competition from generic drugs, which mostly occurs shortly before the expiration of a patented drug and the entry of its generic counterpart and if applied inappropriately, could constitute an abuse of market dominance.

Factors for evaluation include whether the new patented drug represents a non-substantial improvement and whether the transition hinders or delays the entry of generics into the market, according to the guidelines.

"This is not about restricting the development of patented drugs but about regulating false innovation that fails to significantly improve a drug's efficacy, safety or utility," Zhou said.

Comprising seven chapters and 55 articles, the guidelines aim to provide detailed interpretations of monopolistic practices, enforcement principles and criteria for determining violations, offering a comprehensive framework to tackle anti-competitive behaviors in the pharmaceutical industry.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 成人无码T髙潮喷水A片小说 | 日产一一到六区麻豆 | 女生羞羞网站 | 欧美久草 | 日日日日干 | 亚洲精品视 | 久久久久久99 | 日韩伦理免费在线观看 | 日本hdxxxxx护士免费的 | 精品视频www| www.热 | 在线一区免费视频播放 | 日本粉嫩一区二区三区视频 | a国产精品 | 精品久久一区 | 成人午夜AV亚洲精品无码网站 | 国产精品999 | q2002在线观看免费 | 成人国产在线观看 | 三级国产短视频在线观看 | 日日夜夜天天久久 | 日韩欧美中文在线 | 91久久老司机福利精品网 | 免费香蕉视频 | 国产全肉乱妇杂乱视频 | 成人黄色免费视频 | 精品欧美一区二区久久久伦 | 国产福利视频在线观看 | 欧美高清在线精品一区二区不卡 | 香港三级日本三级韩国a | 涩涩97| 精品国产一区二区三区久久久 | 久久国产欧美日韩精品 | 精品国产18久久久久久二百 | 手机国产日韩高清免费看片 | 小明看看在线视频 | 亚洲成av人在线视 | 精品特级毛片 | 一级毛片免费电影 | 一本色道久久88加勒比—综合 | 国产精品福利短视在线播放频 |